[Fabry disease (cardiac lysosomal storage disease) associated with heart failure].
Takenaka
Toshihiro
T
Department of Cardiovascular, Respiratory and Metabolic Medicine, Kagoshima University.
Tei
Chuwa
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D041321:Chromosomes, Human, X / Q000235:genetics; D000795:Fabry Disease / Q000150:complications / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D006333:Heart Failure / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D000519:alpha-Galactosidase / Q000235:genetics / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007527:Isoenzymes; D011994:Recombinant Proteins; D000519:alpha-Galactosidase; C459420:agalsidase beta